Inlyta

Axitinib, the active ingredient in Inlyta, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats metastatic renal cell carcinoma in adult patients.\n\nGNH India supplies Inlyta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Inlyta is a targeted anti‑angiogenic agent used in the management of renal cell carcinoma.\n\nMetastatic renal cell carcinoma: improves progression‑free survival and delays disease progression.

Common Side Effects:\n- Hypertension\n- Diarrhea\n- Fatigue\n- Nausea\n- Decreased appetite\n- Hand‑foot syndrome\n\nSerious or Rare Side Effects:\n- Arterial thromboembolic events\n- Gastrointestinal perforation or fistula\n- Hepatic failure\n- Severe hemorrhage\n- Wound healing complications\n- Life‑threatening hypertension

Patients should be monitored regularly for cardiovascular and hepatic safety.\n\nMonitor blood pressure: check regularly and manage hypertension promptly\nAssess liver function: perform baseline and periodic hepatic enzyme tests\nEvaluate bleeding risk: avoid concomitant anticoagulants unless necessary\nReview cardiovascular history: caution in patients with prior arterial events\nAdjust dose in hepatic impairment: follow prescribing guidance for liver dysfunction\nStore at below 25°C: keep in the original pack, protect from moisture.

Axitinib may interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase axitinib exposure\n- Strong CYP3A4 inducers (e.g., rifampin): may reduce axitinib efficacy\n- Anticoagulants (e.g., warfarin): increased risk of bleeding\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may exacerbate hypertension and bleeding risk\n- Diuretics: may affect blood pressure control\n- CYP2C19 inhibitors (e.g., fluoxetine): modest increase in axitinib levels\n- CYP2C9 inhibitors (e.g., amiodarone): potential elevation of plasma concentrations\n- St. John’s wort: may lower axitinib concentrations